Migraine| Special Topics | CGRP Inhibitors | US | 2017
The migraine market stands on the verge of a renaissance; new and exciting therapies targeting the CGRP peptide could reach the market beginning in 2018. Two broad types of approaches are in final stages of development: monoclonal antibodies (MAbs) against CGRP or the CGRP receptor, and oral inhibitors of the CGRP receptor. Teva, Lilly, Alder, Amgen, and Novartis are developing MAbs for the prophylactic treatment of migraine; meanwhile, Allergan and Merck are developing oral inhibitors against the CGRP receptor for the preventative and acute treatment of migraine. With the imminent release of Phase III data and unique value propositions, how will neurologists view and incorporate an array of CGRP-targeted therapies? How would these compete with the numerous generics on the market and Botox?
QUESTIONS ANSWERED
How will migraine prophylaxis change with the launch of the CGRP-targeted therapies? In which lines of therapy and patient types do neurologists anticipate using these agents?
How might neurologists use anti-CGRPMAbs versus oral inhibitors in the migraine prophylaxis treatment algorithm? What are neurologists’ views of the two therapeutic approaches?
Which of the CGRP-targeted MAbs do surveyed physicians find most promising? How do surveyed neurologists believe these agents compare with Botox, and how will Botox use change?
What are neurologists’ views on oral CGRP antagonists in development? How burdensome do surveyed neurologists expect prescribing restrictions on these agents to be?
PRODUCT DESCRIPTION
Special Topics: Primary market research studies providing physician insights on trends and events affecting the broader industry to help you better anticipate your competitive position.